爱美客股价上涨1.83% 上半年营收净利双降引关注

Core Viewpoint - Aimeike's stock price has shown a slight increase, but the company is facing significant challenges with declining revenues and profits for the first half of 2025, marking the first decline in semi-annual performance since its listing [1] Financial Performance - As of August 22, 2025, Aimeike's stock price is 192.58 yuan, up 1.83% from the previous trading day [1] - The trading volume for the day was 49,534 lots, with a total transaction amount of 944 million yuan [1] - In the first half of 2025, Aimeike reported revenue of 1.299 billion yuan, a year-on-year decrease of 21.59% [1] - The net profit attributable to shareholders was 789 million yuan, down 29.57% year-on-year [1] - The company's core products, "Haitai" and "Rubai Angel," experienced revenue declines of 23.79% and 23.99%, respectively [1] Business Operations - Aimeike specializes in the research, production, and sales of medical beauty products, including solution-based and gel-based injection products [1] - The company's products are used in non-surgical medical beauty fields, providing related products and services to downstream medical institutions [1] Legal Issues - Following the acquisition of South Korea's REGEN company, Aimeike is involved in a dispute over agency rights, facing a compensation claim of 1.6 billion yuan [1] Market Activity - On August 22, 2025, the net inflow of main funds into Aimeike was 23.0628 million yuan, with a cumulative net inflow of 36.8439 million yuan over the past five days [1]